Radar · Life Sciences in Lyon
Best Life Sciences Companies in Lyon, France
The 73 best Life Sciences companies in Lyon, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Valneva.
By Rohit KhannaTrends & Stories
73companies tracked
$655.5Mdisclosed funding
0unicorns
32have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × LYON
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 62% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
62%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2015median founding year
222kcombined LinkedIn audience
43%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Lyon
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Valneva Developer of prophylactic vaccines for infectious diseases | $144M | 44 mo ago | Public | Thomas Lingelbach President & CEO | 1999 | WordPressMySQLPHP+24 | 195 patents Viral vaccine production and subunit vaccine formulation for chikungunya and respiratory pathogens | — |
| 2 | Enyo Pharma Developer of therapeutics for diseases with impaired kidney function 60Patents top 20%Innovation top 21%Funding top 25%Moat top 26% All 9 signals ▾Patentstop 20% Innovationtop 21% Fundingtop 25% Moattop 26% Growthtop 45% Techbottom 49% Globalbottom 43% Marketbottom 40% Newsbottom 27% Patents: 164 patents matched (strict assignee match) · 114 filings since 2022 vs 50 in 2017-21 Innovation: 164 patents (top 16% of patent-holders) · 114 filings since 2022 vs 50 in 2017-21 rank vs industry peers · Fliar Intelligence Index 60/100 | $113M | 12 mo ago | Series C | — | 2014 | WordPress Block EditorWordPressMySQL+18 | 164 patents Patents concentrated in health & consumer products | — |
| 3 | Inova Cloud-based biopharma CRM and CRO collaborating system for the life science industry | $71M | 59 mo ago | Series C | David Carteret Co-Founder | 2010 | — | 5 patents Heat‑resistant culinary apparel with elastic closures for improved chef comfort | — |
| 4 | EYE TECH CARE Developer of ultrasound device to treat glaucoma | $52M | 45 mo ago | Series D | — | 2008 | TYPO3 CMSPHPBootstrap+7 | 111 patents Patents concentrated in health & consumer products | — |
| 5 | Poxel Developer of therapeutic solutions for the treatment of Type 2 diabetes | $50M | 46 mo ago | Public | Thomas Kuhn Co-Founder & CEO | 2009 | BootstrapApache HTTP ServerjQuery+7 | 338 patents Deuterated small‑molecule drugs targeting metabolic, neurological and rare genetic disorders. | — |
| 6 | MaaT Pharma Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases | $42M | 59 mo ago | Public | Herve Affagard Founder and Chief Executive Officer | 2014 | WordPressMySQLPHP+25 | 171 patents Patents concentrated in health & consumer products | 1 internship |
| 7 | Mablink Provider of Antibody-Drug-Conjugates (ADC's) technology for cancer treatment | $35M | 44 mo ago | Acquired | Charles Dumontet Co-Founder | 2018 | — | — | — |
| 8 | Osivax Developer of vaccines against constantly mutating pathogens 32Growth top 28%Funding top 37%Moat top 37%Patents top 40% All 10 signals ▾Growthtop 28% Fundingtop 37% Moattop 37% Patentstop 40% Innovationtop 49% Globalbottom 45% Techbottom 37% Marketbottom 33% Newsbottom 21% Fin. healthbottom 15% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $31.8M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $32M | 15 mo ago | Series B | — | 2017 | WordPressMySQLPHP+24 | 16 patents mRNA and protein-based vaccine formulation and immunogenic composition development | — |
| 9 | Adocia Developer of therapeutics for the treatment of diabetes and obesity 45Product top 14%Patents top 28%Innovation top 35%Funding top 35% All 11 signals ▾Producttop 14% Patentstop 28% Innovationtop 35% Fundingtop 35% Moattop 35% Markettop 49% Growthbottom 47% Techbottom 45% Globalbottom 43% Fin. healthbottom 35% Newsbottom 30% Product: 5 distinct product lines · Company stage: Public Patents: 684 patents matched (strict assignee match) · 119 filings since 2022 vs 272 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $26M | 6 mo ago | Public | — | 2005 | WordPressApple iCloud MailMicrosoft 365+23 | 672 patents Patents concentrated in health & consumer products | — |
| 10 | NH TherAguix Developer of nanoparticle-based theranostic for the treatment of cancer | $16M | 86 mo ago | Series A | — | 2015 | — | 94 patents Nanoparticle-based drug delivery and radiopharmaceutical imaging/therapy | — |
| 11 | GenOway Provider of transgenic rodent models and customized cell lines for preclinical development | $12M | 77 mo ago | Public | — | 1999 | WebflowMatomo AnalyticsGoogle Analytics+16 | 15 patents Genetically engineered animal models with conditional KO/KI and advanced cloning vectors | 1 partnership |
| 12 | NETRI Developer of microfluidic devices for industrial applications | $9M | 16 mo ago | Series A | Florian Larramendy CEO - CTO - Co-founder | 2018 | WordPressMySQLPHP+34 | 33 patents Microfluidic cell‑culture platforms integrating humidification and large‑scale neural activity assays | 2 partnerships |
| 13 | Netris pharma Developer of therapeutic solutions to treat cancer | $8M | 30 mo ago | Series A | — | 2008 | WordPressPleskMySQL+20 | 120 patents Patents concentrated in chemistry & materials | — |
| 14 | Tollys Developer of drugs for treating cancer | $7M | 71 mo ago | Series A | Serge Lebecque Co-Founder & CEO | 2015 | — | 10 patents TLR3 agonist immunomodulators for epithelial and myeloid cell activation in therapeutics | — |
| 15 | Fabentech Developing polyclonal antibodies to treat infectious diseases such as avian influenza, ebola etc. | $7M | 42 mo ago | Series A | — | 2009 | WordPressMySQLPHP+5 | 6 patents Recombinant antibody production for passive immunotherapy against H5N1 influenza | — |
| 16 | Blink Biomedical Antibody-based checkpoint inhibitors for oncology. | $6M | 119 mo ago | Series A | Jack Elands Chief Executive Officer | 2015 | — | 25 patents Therapeutic antibodies for nicotine addiction and CD96-mediated immune modulation | — |
| 17 | ErVimmune Developer of immunotherapies for the treatment of cancer 16News top 36%Moat top 38%Funding top 40%Patents top 44% All 9 signals ▾Newstop 36% Moattop 38% Fundingtop 40% Patentstop 44% Talentbottom 49% Innovationbottom 48% Globalbottom 36% Marketbottom 25% Techbottom 23% News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 16/100 | $5M | 5 mo ago | Series A | Stephane Depil Founder | 2019 | WordPressApple iCloud MailMicrosoft 365+16 | 9 patents Patents concentrated in chemistry & materials | 1 job opening |
| 18 | Bioxis Developing regenerative medical products in the dermatology and medical aesthetic fields | $3M | 117 mo ago | Series A | Frederic Bertaina Founder & CEO | 2010 | PHPZURB FoundationPrototype+9 | — | — |
| 19 | LXRepair Provider of multiplexed assays for determination of the enzymatic status of cellular DNA repair | $3M | 85 mo ago | Seed | Sylvie Sauvaigo Founder & CEO | 2013 | — | 7 patents DNA repair profiling assays for tumor radiosensitivity and toxicity prediction | — |
| 20 | Allogenica Biotechnology company specializing in the development of allogeneic CAR-T therapies for cancer treatment | $3M | 15 mo ago | Funding Raised | Inna Menkova Co-Founder & CEO | 2022 | WixSentryApple iCloud Mail+13 | — | — |
| 21 | Elsalys Biotech Develops therapeutic monoclonal antibodies for cancer and inflammatory diseases | $3M | 65 mo ago | Acqui-Hired | — | 2013 | — | 17 patents Immunotherapeutic agents targeting CD160 and TYRO3 receptors for disease treatment | — |
| 22 | Laclarée Developer of an eye-wear solution for presbyopia correction | $2M | 16 mo ago | Seed | Bruno Berge Founder & CEO | 2016 | WordPressApple iCloud MailMySQL+22 | — | — |
| 23 | Calixar Specializes in the functional and native isolation of complex therapeutic targets & antigens | $2M | 89 mo ago | Series A | — | 2011 | Webflow EcommerceCart FunctionalityWebflow+16 | 31 patents Patents concentrated in health & consumer products | — |
| 24 | StromaCare Developer of immunotherapy for the treatment of solid tumors | $2M | 48 mo ago | Seed | — | 2020 | — | — | — |
| 25 | CTIBiotech Develops 3D human tissue models 19Tech top 45%Talent bottom 49%Funding bottom 47%Global bottom 29% All 5 signals ▾Techtop 45% Talentbottom 49% Fundingbottom 47% Globalbottom 29% Marketbottom 25% Tech: 17 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 19/100 | $1M | 1 mo ago | Funding Raised | Nico Forraz CEO | 2009 | Hostinger Website BuilderNginxOpenResty+14 | — | 2 launchs · 1 partnership · 1 award |
| 26 | Alma Bio Therapeutics Developer of immunomodulatory drugs for the treatment of autoimmune diseases | $1M | 78 mo ago | Seed | — | 2013 | — | — | — |
| 27 | ETISENSE Developer of a wearable cardio-respiratory monitoring device | $508K | 71 mo ago | Seed | Timothe Flenet Co-Founder & CEO | 2017 | — | 14 patents Wearable inductive plethysmography vests for physiological monitoring of small mammals | 1 partnership |
| 28 | Nova In Silico Developer of AI-driven in silico clinical trial platform for improving decision-making in biology, medicine… | $310K | 129 mo ago | Funding Raised | François-Henri Boissel Co-founder & CEO | 2010 | WordPressMySQLPHP+18 | — | 1 launch |
| 29 | Adjuvatis Developer of biodegradable vaccine adjuvants called i-Particles. | $306K | 103 mo ago | Funding Raised | Charlotte Primard CEO | 2013 | — | — | — |
| 30 | TheraPPI Biotech company developing protein interaction solutions for cancer and related diseases | $113K | 15 mo ago | Seed | Stephane Giraud Co-Founder | 2023 | — | — | — |
| 31 | Imaxio Developer of vaccines against typhoid, cholera, and leptospirosis | $41K | 113 mo ago | Funding Raised | Christian Pradeyrol CEO | 2006 | — | 57 patents Engineered coiled‑coil proteins and influenza nucleoprotein recombinant vaccines | — |
| 32 | Inpart Platform connecting scientific decision makers with research, assets, and expertise | — | 59 mo ago | Seed | Gilles Toulemonde Co-Founder & CEO | 2010 | SanityApple iCloud MailMicrosoft 365+17 | — | — |
Top 12 Life Sciences companies in Lyon
#1
Public · Lyon, Auvergne Rhone Alpes · founded 2005 · 111 employees$26Mraised▾
Public · Lyon, Auvergne Rhone Alpes · founded 2005 · 111 employees
Developer of therapeutics for the treatment of diabetes and obesity. Its proprietary platform called the 'Biochaperone' enhances the effectiveness and safety of therapeutic proteins and enables easier usage on patients. Their clinical pipeline includes a unique formulation of PGDF-BB for the treatment of diabetic foot ulcers and insulin formulations for the treatment of diabetes.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Patents
top 28%Innovation
top 35%Funding
top 35%Moat
top 35%Market
top 49%Product: 5 distinct product lines · Company stage: Public
Patents: 684 patents matched (strict assignee match) · 119 filings since 2022 vs 272 in 2017-21 · Latest publication 2026
Innovation: 684 patents (top 4% of patent-holders) · 119 filings since 2022 vs 272 in 2017-21 · 5 product lines
Audience (LinkedIn): 13k LinkedIn followers — 5.9% of this cohort's audience
Funding rounds
- Dec 2025Post IPO$11.7M
- Feb 2025Post IPO$10.2M
- Oct 2019Conventional Debt$16.5M
- Jan 2010Series B$14M
Investors
Bioam, Idinvest Partners, Smalt Capital, CDC Enterprises, IPF Partners, Stifel
Tech stack
All In One SeoApache Http ServerApple Icloud MailBootstrapComplianzContact Form 7
#2
Series C · Lyon, Auvergne Rhone Alpes · founded 2014 · 34 employees$113.5Mraised▾
Series C · Lyon, Auvergne Rhone Alpes · founded 2014 · 34 employees
Developer of therapeutics for diseases with impaired kidney function. The company offers VONAFEXOR is a small molecule with strong fibrolytic and anti-inflammatory properties in both organs, kidney and liver.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Patents
top 20%Innovation
top 21%Funding
top 25%Moat
top 26%Growth
top 45%Tech
bottom 49%Patents: 164 patents matched (strict assignee match) · 114 filings since 2022 vs 50 in 2017-21 · Latest publication 2026
Innovation: 164 patents (top 16% of patent-holders) · 114 filings since 2022 vs 50 in 2017-21
Funding: Raised $113M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Series C (Jun 2025)
Audience (LinkedIn): 9k LinkedIn followers — 4.0% of this cohort's audience
Funding rounds
- Jun 2025Series C$6.9M
- Jan 2024Series C$42.8M
- Oct 2018Grant (prize money)$2.8M
- Jun 2018Series B$46.6M
Investors
Sofinnova Partners, Bpifrance, Morningside, Europa, Orbimed, Andera Partners
Tech stack
BootstrapCloudflareCloudflare Bot ManagementEnyoFont AwesomeGoogle Analytics
#3
Series A · Lyon, Auvergne Rhone Alpes · founded 2019$4.8Mraised▾
Series A · Lyon, Auvergne Rhone Alpes · founded 2019
Developer of immunotherapies for the treatment of cancer. The company combines cancer vaccines and T-cell therapies to create treatments based on the identification of new families of tumor antigens.
Fliar Intelligence Index™ 16how this company ranks against its industry peers
News
top 36%Moat
top 38%Funding
top 40%Patents
top 44%Talent
bottom 49%Innovation
bottom 48%News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding
Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents
Funding: Raised $4.8M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series A (Jan 2026)
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Bioinformatics Engineers, Data Scientists – Immuno-Oncology
Funding rounds
- Jan 2026Series A$19.8M
- Jun 2023Grant (prize money)$15.4M
- Jan 2023Seed$4.8M
Founders & team
Investors
EIC Fund, Seventure Partners, Bpifrance, SPRIM Global Investments
Tech stack
Apple Icloud MailComplianzDiviFont AwesomeGoogle Font ApiJquery
#4
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2009$1.5Mraised▾
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2009
CTIBiotech is a developer of 3D human tissue models for the pharmaceutical industry and dermato-cosmetics sectors. The company also claims of printing cancer tissues in 3D using the tools in bioengineering. It offers 3D tissue and cell models to the pharmaceutical industry for cancer research, regenerative medicine, medical devices, public and private research institutions, and organizations. Offers human biological sample procurement & cell harvesting.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Tech
top 45%Talent
bottom 49%Funding
bottom 47%Global
bottom 29%Market
bottom 25%Tech: 17 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services · Devops: Nginx
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding: Raised $1.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Grant (prize money) (Apr 2026)
Audience (LinkedIn): 8k LinkedIn followers — 3.5% of this cohort's audience
Activity (LinkedIn): 2 product launches · 1 partnerships · 1 awards (incl. KOSÉ Corporation) announced in 12 mo
Funding rounds
- Apr 2026Grant (prize money)$1.5M
Founders & team
Investors
Bpifrance, Government of France
#5
Series B · Lyon, Auvergne Rhone Alpes · founded 2017 · 40 employees$31.8Mraised▾
Series B · Lyon, Auvergne Rhone Alpes · founded 2017 · 40 employees
Developer of vaccines against constantly mutating pathogens. The company leverages oligoDOM a novel proprietary nanoparticles technology specifically designed to trigger superior T-cell responses. The company's lead candidate is OVX836 against influenza and coronavirus.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Growth
top 28%Funding
top 37%Moat
top 37%Patents
top 40%Innovation
top 49%Global
bottom 45%Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Funding: Raised $31.8M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) · Last round Series B (Mar 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 16 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 8k LinkedIn followers — 3.7% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Chargé(e) de Biochimie analytique, Chargé(e) de Purification des Protéines
Activity (LinkedIn): 1 partnerships (incl. CEPI) announced in 12 mo
Funding rounds
- Mar 2025Series B$10.5M
- Dec 2023Grant (prize money)—
- Mar 2023Grant (prize money)$1M
- Jun 2022Grant (prize money)$10.5M
Investors
Noshaq, Anaxago, Bpifrance, NIAID, Gates, EIC Fund
Tech stack
Contact Form 7CookieyesCore-JsElementorEssential Addons For ElementorFont Awesome
#6
Series A · Lyon, Auvergne Rhone Alpes · founded 2018 · 45 employees$8.9Mraised▾
Series A · Lyon, Auvergne Rhone Alpes · founded 2018 · 45 employees
Developer of microfluidic devices for industrial applications. The company has NeoBento a microfluidic platform that focuses on the development of next-generation 3D brain-on-a-chip models for the treatment of neurological diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 11k LinkedIn followers — 5.0% of this cohort's audience
Activity: 2 partnerships (incl. NAMs IAMPS and Japan) announced in 12 mo
Funding rounds
- Feb 2025Series A$5.1M
- Mar 2022Series A$8.9M
Founders & team
Investors
Polygone, NetAngels, Neovacs, Bpifrance, Altana Investissements
Tech stack
All In One SeoApache Http ServerBootstrapCloudflareCloudflare Bot ManagementComplianz
#7
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2022$2.7Mraised▾
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2022
Biotechnology company specializing in the development of allogeneic CAR-T therapies for cancer treatment. It uses healthy donor hematopoietic stem cells as the starting material, rather than the patient's own T cells. Company stem cells are bioengineered to express the CAR and then differentiated into immature precursor T cells called CAR-pre-T cells.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Mar 2025Grant (prize money)$2.7M
Founders & team
Investors
Diplomatie
Tech stack
Apple Icloud MailBootstrapGoogle CloudGoogle Cloud CdnGsapHsts
#8
Seed · Lyon, Auvergne Rhone Alpes · founded 2016 · 10 employees$2.2Mraised▾
Seed · Lyon, Auvergne Rhone Alpes · founded 2016 · 10 employees
Laclaree is the developer of an eye-wear solution for presbyopia correction. The platform has developed the eyeglasses that can be powered with rechargeable batteries and then this electronic hardware is placed in eyeglass frames. Its technology uses a refraction-based solution using liquids that can be inserted in the lense that helps to improve vision.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 1 awards · 1 expansions announced in 12 mo
Funding rounds
- Jan 2025Seed$3.6M
- Jan 2025Grant (prize money)$2.6M
- Jun 2020Grant (prize money)$56.2K
- Jan 2020Grant (prize money)$56.1K
Founders & team
Investors
Europa, Kreaxi, Bpifrance, HTGF, EIC Fund, EIC Accelerator
Tech stack
Apple Icloud MailChart.JsContact Form 7Font AwesomeGoogle Font ApiGoogle Maps
#9
Public · Lyon, Auvergne Rhone Alpes · founded 1999 · 719 employees$143.6Mraised▾
Public · Lyon, Auvergne Rhone Alpes · founded 1999 · 719 employees
Developer of prophylactic vaccines for infectious diseases. The company's lead candidate is VLA1553 is a live-attenuated, single dose vaccine targeting the chikungunya virus. Other products includes VLA15 for Lyme Disease, VLA84 for Clostridium difficile, and VLA1601 for zika virus
LinkedIn Pulse recent public activity · Jul 2026
Audience: 58k LinkedIn followers — 25.9% of this cohort's audience
Funding rounds
- Oct 2022Post IPO$102M
- Jun 2022Post IPO$94.9M
- Feb 2022Grant (prize money)—
- Nov 2021Post IPO—
Founders & team
Investors
European Investment Bank, Bpifrance, Deep Track Capital, CEPI, Scottish Investment Bank, Pfizer
Tech stack
Apache Http ServerCdnjsCloudflareCloudflare Bot ManagementContact Form 7Cookieyes
#10
Public · Lyon, Auvergne Rhone Alpes · founded 2009 · 37 employees$50.4Mraised▾
Public · Lyon, Auvergne Rhone Alpes · founded 2009 · 37 employees
Developer of therapeutic solutions for the treatment of Type 2 diabetes. It offer products for metabolic diseases with a focus on Type 2 diabetes. Its lead candidate is Imeglimin, an orally active adjunct for diet and exercises to improve glycemic control in patients with type 2 diabetes is a mitochondrial bioenergetics enhancer. Its other products include PXL770, an AMP kinase inhibitor for Type 2 diabetes; PXL007, a FxR agonist for Hepatitis B. Also discovering small molecules targeting GLP-1 receptor, the FXR (farnesoid X receptor) as well as on glucokinase activators and 11-B HSD inhibitor.
Funding rounds
- Aug 2022Post IPO$6.1M
- May 2020Post IPO$19.3M
- Jul 2016Post IPO$29.2M
- Jul 2015Post IPO$21.9M
Founders & team
Investors
Edmond de Rothschild, Omnes Capital, INNOBIO, Bpifrance, Kreos Capital, Roivant Sciences
Tech stack
Apache Http ServerBootstrapDocusignFancyboxGoogle Font ApiJquery
#11
Series D · Lyon, Auvergne Rhone Alpes · founded 2008 · 19 employees$51.6Mraised▾
Series D · Lyon, Auvergne Rhone Alpes · founded 2008 · 19 employees
EYE TECH CARE has developed a CE and CFDA approved ultrasound device. The flagship product, EyeOP1 offers a non-invasive treatment for refractory glaucoma. The procedure is performed under local anesthesia. The device is positioned on the patient's eye and the transducer delivers ultrasound energy to reduce intraocular pressure.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Sep 2022Series D—
- Jan 2016Series D$27.3M
- Mar 2013Series C$13M
- Jul 2010Series B$9.4M
Investors
Everpine Capital, China Medical System, Sham, Omnes Capital, CEA Investissement, Kreaxi
#12
Acquired · Lyon, Auvergne Rhone Alpes · founded 2018 · 29 employees$35Mraised▾
Acquired · Lyon, Auvergne Rhone Alpes · founded 2018 · 29 employees
Provider of Antibody-Drug-Conjugates (ADC's) technology for cancer treatment. It offers its propriety hydrophilic linker platform and Mablink’s approach for developing the drug. It forms a non-polymeric of MW 2.0 kD linker which is plasma-stable homogeneous ADCs and doesn't require a site-specific conjugation to binds. The products include MBK-101, MBK-102 for Acute myeloid leukemia, and Multiple myeloma.
Funding rounds
- Oct 2022Series A$30.2M
- Apr 2021Seed$4.8M
- 2018Grant (prize money)$1.7M
Founders & team
Investors
Elaia, Pertinence Invest, Fournier-Majoie Foundation, Sham, Credit Agricole, Sofinnova Partners
Funding & investor landscape
$655.5Mtotal disclosed funding
31companies funded
102disclosed rounds
1rounds last 90 days
Most active investors
Bpifrance15 rounds
Omnes Capital3 rounds
Notable founders
Stephane Depil
Founder · ErVimmune
Nico Forraz
CEO · CTIBiotech
Florian Larramendy
CEO - CTO - Co-founder · NETRI
Thibault Honegger
Co-Founder & CEO · NETRI
Inna Menkova
Co-Founder & CEO · Allogenica
Bruno Berge
Founder & CEO · Laclarée
Thomas Lingelbach
President & CEO · Valneva
Thomas Kuhn
Co-Founder & CEO · Poxel
Sebastien Bolze
Co-Founder · Poxel
Charles Dumontet
Co-Founder · Mablink
Warren Viricel
Co-Founder · Mablink
David Carteret
Co-Founder · Inova
Prism market signals · France · country-scoped Prism corpus, 2,021,151 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN LYON · Health & Bio
How research on Biotechnology in Lyon is moving
A read on the academic research around Biotechnology in Lyon — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 41 papers.
41 papers · stance +0.40 · 40% breakthrough · 29% concern
top institutions
- Université Claude Bernard Lyon 114
- Ecologie Microbienne Lyon10
- Hospices Civils de Lyon5
- Institut National des Sciences Appliquées de Lyon4
- École Normale Supérieure de Lyon3
leading researchers
Adem Gharsallaoui · Bryce E. Clifton · Christopher J. K. Wan · Edoardo Gianni · Kevin Goeij · Nadia Oulahal
prism intelligence · tone & topics
98% positive · 2% critical tone
HealthMedical ResearchAgricultureGeneticsPharmaceuticalsBiology
▲
Breakthroughs14 · 34%
▼ 50%→39% share
▼0.8× share momentum0 median citations93% since 2021mostly methods-led
Breakthroughs are cooling (50%→39% of field), led by Ribozyme.
rising sub-themes (early→recent)
- Ribozyme2
- Polymerase2
- Ligase ribozyme2
- RNA polymerase I2
- RNA polymerase2
Landmark Osteal Tissue Macrophages Are Intercalated throughout Human and Mouse Bone Lining Tissues and Regulate Osteoblast Functi · 685 cites
◆
Advancements11 · 27%
▼ 50%→24% share
▼0.5× share momentum0 median citations73% since 2021mostly empirical
Advancements are cooling (50%→24% of field), led by Antimicrobial.
rising sub-themes (early→recent)
- Antimicrobial2
- Genome2
- Essential oil1
- Antibacterial activity1
- Vanillin1
Landmark Gadolinium Chelate Coated Gold Nanoparticles As Contrast Agents for Both X-ray Computed Tomography and Magnetic Resonanc · 519 cites
▼
Concerns10 · 24%
▲ 0%→27% share
0 median citations90% since 2021mostly empirical
Concerns are rising (0%→27% of field), led by Antibiotics.
rising sub-themes (early→recent)
- Antibiotics2
- Antibiotic resistance2
- Antibody2
- Microbiome1
- Microbiology1
Landmark In-feed antibiotic effects on the swine intestinal microbiome · 1,074 cites
Common questions
How many Life Sciences companies are there in Lyon, France?
Radar tracks 73 indexable Life Sciences companies headquartered in Lyon, France that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Lyon, France?
The Life Sciences companies in Lyon, France on this list have raised a combined $655.5M in disclosed equity funding across 31 funded companies.
Which is the highest-funded Life Sciences company in Lyon, France?
Valneva is the highest-funded Life Sciences company in Lyon, France, with $143.6M in disclosed equity funding.
How many Life Sciences companies in Lyon, France are funded?
31 of the 73 Life Sciences companies in Lyon, France on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Lyon, France?
None of the Life Sciences companies in Lyon, France on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Lyon, France Life Sciences companies?
The most active investors in Lyon, France Life Sciences companies on this list include Bpifrance, Europa, Kreaxi, BigBooster, EIC Fund.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.